Get startedLog in
    Picture of Esperion Therapeutics logo

    ESPR — Esperion Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareSpeculativeMid CapValue Trap
    All News

    Brief: Esperion’s Bempedoic Acid Receives Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidaemias

    Picture of Esperion Therapeutics logoEsperion Therapeutics
    29/08/2025 13:03
    Aug 29 (Reuters) - Esperion Therapeutics Inc ESPR.O:

ESPERION’S BEMPEDOIC ACID RECEIVES LEVEL 1A RECOMMENDATION IN UPDATED ESC/EAS GUIDELINES FOR MANAGEMENT OF DYSLIPIDAEMIAS

ESPERION THERAPEUTICS INC - BEMPEDOIC ACID RECOMMENDED FOR PATIENTS UNABLE TO TAKE STATIN THERAPY TO ACHIEVE LDL-C GOAL. CLASS I, LEVEL B

Source text: ID:nGNX6G5k4K

Further company coverage: ESPR.O

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Esperion Therapeutics

    See all news